-
Article
Open AccessIsatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial
CD38-targeting immunotherapy is approved in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma (NDMM) that are transplant ineligible (TI) and is considered the be...
-
Article
Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma
-
Article
Improved survival in multiple myeloma during the 2005–2009 and 2010–2014 periods
-
Article
Autologous stem-cell collection following VTD or VRD induction therapy in multiple myeloma: a single-center experience
Triplet-drug regimen bortezomib–thalidomide–dexamethasone (VTD) and bortezomib–lenalidomide–dexamethasone (VRD) are considered as standard of care induction prior autologous stem-cell transplantation (ASCT) in...
-
Article
Open AccessObinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study
GREEN (NCT01905943) is a nonrandomized, open-label, single-arm, phase 3b study investigating the safety and efficacy of obinutuzumab alone or in combination with chemotherapy in chronic lymphocytic leukemia (C...
-
Article
Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma
The combination of pomalidomide and low-dose dexamethasone (Pom-Dex) has proved effective and safe in patients with end-stage relapsed/refractory multiple myeloma (RRMM), otherwise characterized by a very poor...
